Neurovance
Signal active
Organization
Contact Information
Overview
Neurovance is a clinical-stage neuroscience company that discovered and developed centanafadine (CTN) to help adults and children with ADHD.
Neurovance has been funded in a venture capital investment by Novartis Venture Fund, Venture Investors, Tekla Capital Management, GBS Venture Partners, State of Wisconsin Investment Board (SWIB), and Timothy J. Barberich.
It was founded in 2009 and is headquartered in Cambridge, Massachusetts.
About
Industries
Biotechnology, Health Care, Neuroscience, Clinical Trials
Founded
2009
Employees
1-10
Headquarters locations
United States, North America
Social
N/A
Profile Resume
Neurovance headquartered in United States, North America, operates in the Biotechnology, Health Care, Neuroscience, Clinical Trials sector. The company focuses on Biotechnology and has secured $3.1B in funding across 96 round(s). With a team of 1-10 employees, Neurovance is actively contributing to advancements in Biotechnology. Their latest funding round, Venture Round - Neurovance, raised $478.1K. Discover more about their projects, partnerships, and impact on our platform.
Employees
N/A
Funding Rounds
Funding rounds
6
Investors
0
Lead Investors
0
Total Funding Amount
$31.8M
Details
3
Neurovance has raised a total of $31.8M in funding over 3 rounds.
| Announcement date | Transaction name | Number of Investors | Money raised | Lead Investor |
|---|---|---|---|---|
| 2015 | Early Stage Venture | 6.5M | ||
| 2015 | Early Stage Venture | 5.5M | ||
| 2014 | Early Stage Venture | 6.3M |
Investors
Neurovance is funded by 24 investors.
| Investor Name | Lead Investor | Funding Round | Partners |
|---|---|---|---|
| State of Wisconsin Investment Board | - | FUNDING ROUND - State of Wisconsin Investment Board | 7.0M |
| Tekla Capital Management | - | FUNDING ROUND - Tekla Capital Management | 7.0M |
| Neurovance | - | FUNDING ROUND - Neurovance | 7.0M |
| Timothy J. Barberich | - | FUNDING ROUND - Timothy J. Barberich | 7.0M |
Recent Activity
There is no recent news or activity for this profile.